Details of the Drug Combinations

General Information of This Drug (ID: DM4HYMS)

• Drug Name: ABT-888 (DM4HYMS)
• Synonyms: Veliparib; 912444-00-9; ABT-888; ABT 888; ABT-888 (Veliparib); Veliparib (ABT-888); ABT888; UNII-01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; CHEBI:62880; 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide; (R)-2-(2-methylpyrrolidin-2-yl)-1H-benzo[d]imidazole-4-carboxamide; 01O4K0631N; 2-[(2R)-2-Methylpyrrolidin-2-yl]-1H-benimidazole-4-; (2r)-2-(7-Carbamoyl-1h-Benzimidazol-2-Yl)-2-Methylpyrrolidinium; Veliparib dihydrochloride

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Phase 3 [1]; Epithelial ovarian cancer; ICD 11: 2B5D; Status: Phase 3 [2]; Non-small-cell lung cancer; ICD 11: 2C25.Y; Status: Phase 3 [3]; Ovarian cancer; ICD 11: 2C73; Status: Phase 3 [3]; Melanoma; ICD 11: 2C30; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-888 + Ruxolitinib	DC0HPCH	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[4]

11 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-888 + Topotecan	DC0XC45	Topotecan	Ovarian Cancer	[5]
ABT-888 + Temozolomide	DC0Z3KL	Temozolomide	Brain and Central Nervous System Tumors	[6]
ABT-888 + Capecitabine	DCAW4KX	Capecitabine	Locally Advanced Rectal Cancer	[7]
ABT-888 + Cyclophosphamide	DCBE5RD	Cyclophosphamide	Ovarian Cancer	[8]
ABT-888 + Temozolomide	DCKKLEB	Temozolomide	Non-hematologic Malignancies	[9]
ABT-888 + Carboplatin	DCJFEZ5	Carboplatin	Non-Small Cell Lung Cancer	[10]
ABT-888 + Carboplatin	DC707XK	Carboplatin	Cancer - Ovarian	[11]
ABT-888 + Temozolomide	DCCR21I	Temozolomide	Functional Pancreatic Neuroendocrine Tumor	[12]
ABT-888 + Oxaliplatin	DCEE9HL	Oxaliplatin	Adenocarcinoma of the Pancreas	[13]
ABT-888 + Gemcitabine	DCYGHPW	Gemcitabine	Pancreatic Cancer	[14]
Eribulin + ABT-888	DCHQSTE	Eribulin	Breast Cancer Stage IV	[15]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7417).
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [5] ClinicalTrials.gov (NCT01690598) Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
• [6] ClinicalTrials.gov (NCT00770471) ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• [7] ClinicalTrials.gov (NCT01589419) A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
• [8] ClinicalTrials.gov (NCT01306032) Phase II ABT-888 With Cyclophosphamide
• [9] ClinicalTrials.gov (NCT00526617) A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
• [10] ClinicalTrials.gov (NCT02944396) Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
• [11] ClinicalTrials.gov (NCT03400306) A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
• [12] ClinicalTrials.gov (NCT02831179) Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor
• [13] ClinicalTrials.gov (NCT01233505) Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
• [14] ClinicalTrials.gov (NCT01908478) Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer
• [15] ClinicalTrials.gov (NCT03032614) Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients